

Are your MRI contrast agents cost-effective?

Learn more about generic Gadolinium-Based Contrast Agents.



AJNR

Reply:

S. Karimi

AJNR Am J Neuroradiol published online 13 September 2018

<http://www.ajnr.org/content/early/2018/09/13/ajnr.A5826>

This information is current as
of April 10, 2024.

REPLY:

I appreciate the comments in the letter to the Editor and the interest in our publication. The parameters used in our project best fit our dynamic contrast-enhanced (DCE) model with the FDA-approved software. I find the comments interesting and truly hope

that the commentators use their suggestions on their own spine DCE data, and I look forward to their publications in this area along with a discussion of histopathology of hemangiomas.

 **S. Karimi**

Department of Radiology
Memorial Sloan-Kettering Cancer Center
New York, New York

<http://dx.doi.org/10.3174/ajnr.A5826>